Characterization of host immune responses in Ebola virus infections.
about
Addressing Therapeutic Options for Ebola Virus Infection in Current and Future OutbreaksEbolavirus comparative genomicsEbola: translational science considerationsMinimal In Vivo Efficacy of Iminosugars in a Lethal Ebola Virus Guinea Pig ModelModeling of the Ebola virus delta peptide reveals a potential lytic sequence motifEbola virus: A gap in drug design and discovery - experimental and computational perspective.Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials.Contrasting academic and lay press print coverage of the 2013-2016 Ebola Virus Disease outbreak.Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus.The multiple roles of sGP in Ebola pathogenesisEbola virus: a clear and present danger.Immune memory to Sudan virus: comparison between two separate disease outbreaks.Robust and sustained immune activation in human Ebola virus infection.Evaluating large-scale blood transfusion therapy for the current Ebola epidemic in LiberiaBolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola VaccineA Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola InfectionMechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies.Ebola Virus Infection: Overview and Update on Prevention and Treatment.Longitudinal characterization of dysfunctional T cell-activation during human acute Ebola infection.Ebola control: effect of asymptomatic infection and acquired immunityCorrespondence of Neutralizing Humoral Immunity and CD4 T Cell Responses in Long Recovered Sudan Virus SurvivorsIn vivo Ebola virus infection leads to a strong innate response in circulating immune cells.T-cell-dependent mechanisms promote Ebola VLP-induced antibody responses, but are dispensable for vaccine-mediated protection.Innate Immune Responses of Bat and Human Cells to Filoviruses: Commonalities and Distinctions.Sudan ebolavirus long recovered survivors produce GP-specific Abs that are of the IgG1 subclass and preferentially bind FcγRIViral immune surveillance: Toward a TH17/TH9 gate to the central nervous system.Ebola, Through Air or Not Through Air: That is the Question.Reintegration of ebola survivors into their communities - Firestone District, Liberia, 2014.Support services for survivors of ebola virus disease - Sierra Leone, 2014.Identification of Ebola virus microRNAs and their putative pathological function.To hasten Ebola containment, mobilize survivors.Do corticosteroids have a role in treating Ebola virus disease?Estimates of Ebola virus case-fatality ratio in the 2014 West African outbreak.Development and Validation of a Novel Dual Luciferase Reporter Gene Assay to Quantify Ebola Virus VP24 Inhibition of IFN Signaling.A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.Why has the Ebola outbreak in West Africa been so challenging to control?Association between temperature, humidity and ebolavirus disease outbreaks in Africa, 1976 to 2014
P2860
Q26801423-9BA72007-E876-41EB-A029-5DCFCD14147CQ26801790-362B6496-1959-4838-8EED-664A690FEE08Q28082994-63A07C66-8B9B-4BC7-AAD1-A4BB936AA221Q28553683-FCDA47A6-6FA9-47F0-A949-6574AFFBBC28Q28651528-46D17777-0D8C-4757-ABDA-F28F5C322C02Q30243938-14003096-4D05-4B13-8F1F-2D380015F63EQ30251949-04221FC0-6B80-40DD-84D1-CFC0D88E6082Q33825309-D7CC9E98-997B-4C09-8D85-487B492CED50Q34463780-1C295DF1-17CF-4C66-8115-F1274A3F1017Q34869463-22183414-6A3F-4411-9992-DA9DBEFEBC2DQ34917106-52941B29-A490-440C-BAF0-6E46E3E7DED5Q35014908-891D7939-3900-4059-AC32-11F86A34180FQ35485733-1481D81F-7DE0-4FCF-A083-B689B5DC5BADQ35661932-B7174396-348A-4596-8EB4-9E6B0EA49ECDQ35917496-E485B167-BEBF-4A6E-A024-802C2CED2AE9Q35917501-6B97F9E0-CA44-425C-A1B1-25B655599F9FQ36208191-5776CD82-9BF5-4046-AA68-CFAB4440E77BQ36363253-1087F769-D0DE-4ED5-8A11-252174268073Q36775011-BAFFA13D-C80E-45E9-B71E-2D485E3D1E0EQ36791663-AD3AF0DA-9F1B-4D7D-BD03-A9AF351DEE24Q36947021-CCDB55B9-7F16-42FA-B238-A7E4B6D1E581Q37233016-B6C2F363-165B-4488-8785-A99C8D2FB2BAQ38674025-4745207B-DB1D-4E61-AC42-AA4D0B47D2F7Q38719410-B3037A27-9CDB-4D90-AACE-BA3F72BE37BAQ38848145-228F55CC-7F70-44B0-ABBE-6CE4CFAD76E5Q40164925-D5A2D41F-A462-4E54-BDD4-2F558D66C651Q40171222-63D72F89-A746-49B8-815A-2BDB1B816B04Q40177271-17C0D846-B05D-42AC-ABB3-38771E9FF5C5Q40177277-6D2E7C86-87CA-4375-A534-CF591F9E4B01Q40189049-69B9CA2F-837E-48DC-8BEF-16881325C00EQ43079335-0212416C-37A0-4A40-A9F0-1377D24D87A3Q44077034-3C62B549-A3B5-4790-B5FC-3EB31F6BD4B2Q44094633-CAD91887-B4FE-4096-AE47-3ABC4367890CQ51784590-98C47484-EB98-4923-BAF8-E664D432791DQ51785212-6C08CC16-C86D-4AA9-ACC5-AB03E94A8193Q54107710-B5EF1C72-E5D2-4395-A0A8-E9F291CCB9FBQ55981943-ED9E0841-72DB-44C4-8C63-2006489AC4FE
P2860
Characterization of host immune responses in Ebola virus infections.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Characterization of host immune responses in Ebola virus infections.
@en
type
label
Characterization of host immune responses in Ebola virus infections.
@en
prefLabel
Characterization of host immune responses in Ebola virus infections.
@en
P2860
P50
P1476
Characterization of host immune responses in Ebola virus infections.
@en
P2860
P304
P356
10.1586/1744666X.2014.908705
P577
2014-04-18T00:00:00Z